Document is current
Any future updates will be listed below
-
Authors
Jones, Spencer
Mikuls, Ted R.
England, Bryant R.
-
Funding
Funding for this research was provided by:
VA CSR&D Merit (CX002995)
Biomedical Laboratory Research and Development, VA Office of Research and Development (BX003635)
National Institute of General Medical Sciences (U54 GM115458)
National Institute of General Medical Sciences (U54 GM115458)
Department of Defense (PR200793)
VA CSR&D (IK2 CX002203)
- License Information
-
More Information
Article History
Received: 31 December 2025
Accepted: 7 April 2026
First Online: 21 April 2026
Declarations
:
: BRE consulting from Boehringer-Ingelheim and Artiva Biotherapeutics, research support from Boehringer-Ingelheim.TRM has received prior research support from Horizon Therapeutics (Amgen) and has served as a consultant for Horizon, UCB, Merck, Sobi and Olatec Therapeutics.
